European VitreoRetinal Society a certain philosophy

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: Barbara Parolini, Grazia Pertile, Verona, Italy To determine whether macular translocation with 360-degree retinotomy can stabilize and / or improve visual acuity in patients with retinal pigment epithelium (RPE) tear, given the increasing number of reports on this complication following vascular endothelial growth factor (VEGF)-modulating therapy. Methods: Prospective...

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Khaled El Rakhawy, Cairo, Egypt Advantages: In selected cases of myopic CNVM, surgical removal gives better visual outcome and relieves the patient from metamorphopsia as well as from the need to have many repeated injections with only limited improvement or merely stabilization of vision. Large membranes are particularly suitable for this approach. Methods: After complete...

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Klaus Lucke, Bremen, Germany Introduction: Surgical removal of subfoveal CNVs was practiced widely in the 1990s for the treatment of AMD and other exudative maculopathies. Since it virtually always left a large subfoveal RPE defect the visual results were by and large disappointing and the Submacular Surgery Trial (SST) showed that no statistically significant improvement in vision...

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Jean-Paul Amar, Cannes, France Subretinal surgery has slowly disappeared but 75% of eyes with a subretinal heamatoma are lost. The subretinal drainage of the blood and the surgical ablation of the blood neovessels seem to remain still useful with a quite low rate of complications.

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: TL Jackson, M Farah, JP Duprat, M Avila, GY Fujii, J Rossi, A Santos, R Palank , J Nau, London, UK Advantages: Epimacular brachytherapy (EMB) offers a novel, durable, costeffective treatment for age-related macular degeneration. Methods: Patients with classic, mixed or occult choroidal neovascularisation (CNV) underwent a pars plana vitrectomy followed by 24 Gy beta irradiation...

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: Victor N. Kazaykin, Igor A. Malov, Yekaterinburg, Russia Advantages: Combination of laser retinopuncture and 25G endovitreal surgery provides a possibility to obtain attachment of retinal pigment epithelium serous detachment (RPE SD), caused by ARMD, in the macular region in its combination with posterior hyaloid detachment. Methods: After limiting retinal lasercoagulation at...

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Janusz Michalewski, Slawomir Cisiecki, Dominik Odrobina, Krzysztof Dziegielewski, Zbigniew Pikulski, Zofia Michalewska, Maciej Bednarski, Jerzy Nawrocki, Lodz, Poland Advantages: Spectral domain OCT determined anti- VEGF therapy enabled the reduction of number of injections. Moreover Spectral OCT enabled to determine some prognostic factors for anti- VEGF...

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Sengul Ozdek, Cuneyt Ozmen, Berati Hasanreisoglu, Ankara, Turkey Advantages: A new activity scoring (AS) for assessment of the neovascular ARMD activity is defined. AS supplies standardization for the assessment of the lesion activity after anti-VEGF therapy. Methods: 52 eyes with neovascular ARMD treated with anti- VEGF agents were involved. The AS is based on 1) fluid...

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Author: Arwa Azmeh, Damascus, Syria Advantages: A classification of retinal and subretinal morphological changes based on OCT findings was suggested to be used in follow up of activity of CNV secondary to AMD after treatment, and for making the decision of retreatment. Methods: OCT scans through CNV secondary to AMD using Zeiss stratus OCT 3000 were analyzed. The OCT findings were...

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Sengul Ozdek, Cuneyt Ozmen, Berati Hasanreisoglu, Ankara, Turkey Advantages: To define the nonresponders of CNV to anti-VEGF treatment clearly so that unnecessary treatments with a costly agent can be prevented. Methods: A mini questionnaire with 7 items was send to the retina specialist in Turkey via e-mail. The questions were related with the definition of...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Author: Taehyuk Koh, South Korea Advantages: To evaluate the one year outcome for monotherapy of avastin and combined therapy of avastin plus photodynamic therapy (PDT). Methods: Monotherapy group was received avastin 3 times every 6 weeks. In combination group, we started intravitreal avastin one week before and after PDT in the same way. In 49 eyes, we evaluated vision,...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Naples, Italy; Michael J. Potter, Cheryl Claudio, Shelagh M. Szabo, Vancouver, Canada Advantages: To obtain a greater improvement after treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Prospective, randomized, double masked, controlled, interventional study. Thirty five eyes (35 patients) presenting...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Paola Bonavolontà, Naples, Italy; Jean Paul Adenis, Pierre-Yves Robert, Limoges, France Advantages: To reduce the number of retreatments with intravitreal anti- VEGF in exudative age related macular degeneration (AMD). Methods: We evaluated all eyes with exudative AMD treated with bevacizumab or ranibizumab in monotherapy and in association with...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Rosa Maria Romero-Castro, Alfredo Morales, H. Quiroz-Mercado, Mexico Advantages: New modality treatmens are needed to increase effectiveness and reduce number of retreatmens in AMD patients. Triple therapy with PDT, intravitreal triamcinolone and intravitreal ranibizumab can be with less number of treatments and they’re for less cost a safe treatment option for...

http://www.evrs.eu/medias/2009/congress/Anti-VEGF-Alone.flv Author: Ron A. Adelman, New Haven, CT, USA Advantages: Reduction of number of injection, improving compliance Methods: Injection of anti VEGF monthly for 3 months. After three months decision for treatment is based on OCT. Effectiveness / Safety: Improved patient satisfaction.

http://www.evrs.eu/medias/2009/congress/Anti-VEGF-Alone.flv Authors: Ivan Fiser, Frantisek Benda, Prague, Czech Republic Advantages: Tailored therapy with Avastin is an effective treatment of wet AMD. It can reduce the number of applications and save the patients´ money, thus enables more patients to be treated. There are potential super responders to Avastin in whom a single injection is a sufficient treatment. Methods: 274 eyes of 270...

Guy l’Helgoualch, MD (Brest, France) PURPOSE: To check using Avastin in intravitreous injection reduces the surface and the thickness of the neovascular membrane. To check improving the effect of PDT and reducing the side effects increases the final visual acuity. To verify this protocol of tritherapy reduces the number of treatment during the period of follow-up. METHODS: The population of patients includes the same proportion of...

Albert J. Augustin, MD (Sulzfeld, Germany), Indre Offermann, MD (Karlsruhe, Germany), Stephan Puls, MD (Karlsruhe, Germany), Frank H.J. Koch, MD (Frankfurt am Main, Germany), Ursula Schmidt-Erfurth, MD (Vienna, Austria)* PURPOSE: To assess the treatment and outcome of patients with CNV treated with PDT combined with intravitreal triamcinolone (TA). METHODS: Patients (n? 307) suffering from CNV (76.2% subfoveal, 12.1% juxtafoveal, 11.7%...

Asheesh Tewari, MD (St. Louis, MO), Rajendra S. Apte, MD, PhD (St. Louis, MO)* PURPOSE: To examine outcomes of a group of previously treatment naïve patients treated with combined photodynamic therapy with verteporfin and intravitreal pegaptanib for choroidal neovascularization secondary to ARMD. METHODS: Retrospective review of ten eyes of ten consecutive patients with CNV secondary to ARMD. These patients had  not received  any prior...

http://www.evrs.eu/medias/2006/congress/Six-month-Results-of-a-Randomized,-Double-masked,-Controlled-Trial-of-Intravitreal-Triamcinolone-as-an-Adjunct-to-Photodynamic-Therapy-in-Predominantly-Classic-Neovascular-Age-related-Macular-Degeneration:-The-Canadian-RETINA-Study.swf David Maberley, MD, FRCSC, MSc (Vancouver, Canada),* PURPOSE: To compare safety data and ETDRS visual acuity outcomes data for one-hundred subjects with predominantly...

Olcay Tatar, (Tuebingen, Germany), Annemarie Adam, (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Peter Stalmans, MD, PhD (Leuven, Belgium), Claus Eckardt, MD (Frankfurt, Germany), Matthias Lüke, MD (Tuebingen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany), Salvatore Grisanti, MD (Tuebingen, Germany) PURPOSE: To examine the impact of photodynamic therapy (PDT) on pigment epithelium derived factor (PEDF) expression...

Panos Stergiou, (Thessaloniki, Greece), Kostantinos Malamos, MD (Thessaloniki, Greece), Efstathios Dragiotis, MD (Thessaloniki, Greece), Anastasios Felekidis, MD (Thessaloniki, Greece), Tania Karagiani, MD (Thessaloniki, Greece), Stavros Dimitrakos, MD (Thessaloniki, Greece) PURPOSE: To investigate whether combined intravitreal use of triamcinolone (Kenacort) and bevacizumab (Avastin) can prolong the beneficial effect and reduce the need...

http://www.evrs.eu/medias/2006/congress/The-Effect-of-Kenalog-as-Adjunctive-Treatment-to-Visudyne-in-Minimally-Classic-and-Occult-Neovascular-AMD:-A-Prospective,-Randomized-Clinical-Trial.swf Tom Sheidow, MD, FRCS(C) (London, Canada), Varun Chaudhary, MD (London, Canada), Phil Hooper, MD, FRCSC (London, Canada), Alex Mao, MD (London, Canada) PURPOSE: To evaluate the mean change is ETDRS visual acuity score from baseline and the number of...

http://www.evrs.eu/medias/2006/congress/Combined-Intravitreal-Triamcinolone-with-Photodynamic-Therapy-for-the-Treatment-of-Choroidal-Neovascularization-in-Age-Related-Macular-Degeneration.swf Catherine Favard, MD (Paris, France), Valerie Krivosic, MD (Paris, France), Lucie Machado, DO (Paris, France), Michael Assouline, MD, PhD (Paris, France), Catherine Francais, MD (Paris, France) PURPOSE: To determine whether photodynamic therapy (PDT)...

Gÿng.sr Sobaci, MD (Ankara, Turkey), Melih Osman Çeylan, MD (Ankara, Turkey), Sayih Altun, MD (Ankara, Turkey), Seçkin Aykas, MD (Anakar, Turkey), Mehmmet Zeki Bayraktar, MD (Ankara, Turkey) PURPOSE: We previously showed that hypericin, the most powerful natural photoactive pigment can induce development of photothrombosis in the choriocapillaries when activated with argongreen laser at light fluences causing subthreshold burn Efficacy...

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: An update of the baseline characteristics of the Anecortave Acetate Risk Reduction Study (AART, C-02-60) evaluating the efficacy and safety of posterior juxtascleral administrations (PJD) of anecortave acetate versus sham in patients at risk for developing sightthreatening choroidal neovascularization (CNV), and of the combination study with an anti-VEGF antiangiogenic agent (Bridge...

Stephen H. Sinclair, MD (Media, PA),* Weiye Li, MD (Media, PA), Peter Presti, (Media, PA)* PURPOSE: Vision outcomes for treatment of AMD CNVM have been previously evaluated using visual acuity with severe limitations. Central visual field testing with discriminated targets appears to offer significant advantages. METHODS: In this cohort, 31 eyes of 29 patients undergoing PDT with intravitreal triamcinolone for AMD CNVM underwent IVFA, BCVA...

Ruth Axer Siegel, MD (Petah Tikva, Israel), Irit Rosenblat, MD (Petah-tikva, Isreal), Anat Loewenstein, MD (Tel Aviv, Israel),* Ludmila Shani, MD (Beer-sheva, Isreal), Adiel Barak, MD (Tel-aviv, Isreal), Tova Lifshitz, MD (Beer-sheva, Isreal), Marina Shneck, MD (Beersheva, Isreal), Amira Springer, MD (Rehovot, Isreal), Ayala Pollack, MD (Rehovot, Israel), Michaela Goldstein, MD (Tel-aviv, Isreal), Joseph Ferentz, MD (Kfar-saba,...

Joerg C. Schmidt, MD (Marburg, Germany), Stefan Mennel, MD (Marburg, Germany), Carsten Meyer, PD, MD (Marburg, Germany), Stefan Hoerle, MD (Marburg, Germany) PURPOSE: Subretinal CNV extraction and macular transposition can be offered to selected patients as a treatment option. When this surgery was first used, the development of PVR was the main postoperative complication, now CNV recurrence is the major problem. METHODS: During the last...

Arturo Santos, MD, PhD (Guadalajara, Mexico), Enrique A. Roig-Melo, MD PhD (Guadalajara, Mexico), Ramon Flores-Fuentes, MD (Guadalajara, Mexico), Juan C. Altamirano, MD (Guadalajara, Mexico) PURPOSE: To evaluate the feasibility and safety of the combination of photodynamic therapy with verteporfin (PDT), intravitreal Bevacizumab and preservative free Triamcinolone acetonide (PFTA) for the treatment of exudative AMD. METHODS: This is a...

http://www.evrs.eu/medias/2006/congress/CLEAR-IT-1:-A-Phase-I-Safety,-Tolerability,-and-Bioactivity-Study-of-Intravitreal-VEGF-Trap-in-Patients-with-Neovascular-AMD.swf Quan Dong Nguyen, MD (Baltimore, MD),* David Browning, MD, PhD (Charlotte, NC),* Peter L. Sonkin, MD (Nashville, TN),* Seenu Hariprasad, MD (Chicago, IL),* Henry L. Hudson, MD, FACS (Tucson, AZ),* Karen Chu, (Tarrytown, NY),* Julia A. Haller, MD (Baltimore, MD), William F....

Edwin H. Ryan, MD (Minneapolis, MN), Lejla Mutapcic, BS (Rochester, MN), Jose S. Pulido, MD (Chicago, IL) PURPOSE: To determine via a retrospective review of treated patients whether thermal laser photocoagulation combined with intravitreal triamcinolone (IVTA) can safely and effectively reduce the risk of neovascular membrane recurrence and vision loss in patients with choroidal neovascularization (CNV). METHODS: We conducted a...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Enhanced-Pegaptanib-(Macugen)-Therapy-for-Choroidal-Neovascularization-in-AMD:-An Avastin-Booster.swf Michael J. Tolentino, MD (Winter Haven, FL),* David M. Misch, MD (Winter Haven, FL), Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, Fl) PURPOSE: The study purpose is to determine if bevacizumab combined with pegaptanib can harness the rapid...

Carl D. Regillo, MD, FACS (Philadelphia, PA),* Neil M. Bressler, MD (Baltimore, MD),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (South San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of less frequent dosing of ranibizumab (LucentisTM) on patientreported visionspecific QoL through 12 months using the NEI-VFQ 25 in PIER, a phase...

Michael J. Potter, MD (Vancouver, Canada),* Shelagh M. Szabo, BSc (Vancouver, Canada) PURPOSE: To compare the incidence of recurrence of CNV at 18 months after treatment with photodynamic therapy (PDT) with verteporfin, and PDT plus intravitreal Kenalog (IVT), in patients with age-related macular degeneration. METHODS: This is a prospective study of consecutive patients treated with PDT alone, or PDT plus IVT at baseline. Final treatment...

http://www.evrs.eu/medias/2006/congress/Combination-Avastin-and-Reduced-Fluence-Photodynamic-Therapy-for-Choroidal-Neovascularization.swf David Callanan, MD (Arlington, TX),* Wayne Solley, MD (Arlington, TX) PURPOSE: The purpose of the study is to determine whether the combination of intravitreal Avastin and reduced fluence PDT is as effective as either treatment alone; and whether the combination therapy may reduce the number of treatments...

Ayala Pollack, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Gennady Landa, MD (Ashkelon, Israel), Yoel Greenwald, MD (Jerusalem, Israel), Haya Katz, MD (Rishon Lezion, Israel), Hana Leiba, MD (Yavneh, Israel) PURPOSE: To evaluate the relationship between cataract surgery, AMD, and PDT outcome. METHODS: All patients underwent both PDT for wet AMD, and cataract surgery by phacoemulsification. They were divided into three...

Gaurav K. Shah, MD (St. Louis, MO), Mandeep S. Dhalla, MD (St. Louis, MO), Kevin J. Blinder, MD (St. Louis, MO), Edwin H. Ryan, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Asheesh Tewari, MD (St. Louis, MO) PURPOSE: To examine the 6-month results of a group of patients treated with combined photodynamic therapy (PDT) with verteporfin with intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to...

Masood Naseripour, MD (Tehran, Iran), Kamran Manshaee, MD (Tehran, Iran), Pejman Bakhtiari, MD (Tehran, Iran), Shabnam Salimi, MD (Tehran, Iran) PURPOSE: To evaluate the role of hyperthermia in control of sufoveal CNV. METHODS: Method: the 93 eyes of 85 consecutive patients with angiographically proved CNV underwent TTT with diode laser emission at 810nm. Mean patients age was 74.0 ± 7.1 years (range: 55-88 years). 59 patients (69.4%)...

Rajeev Hemant Muni, MD (Toronto, Canada), Mike Altaweel, MD (Madison, WI), Matt T. Tennant, MD (Edmonton, Canada), Bruce Weaver, BSc, MSc (Thunder Bay, Canada), Peter J. Kertes, MD, FRCS(C) (Toronto, Canada) PURPOSE: To determine the inter- and intra-observer agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy and the angiographic classification of CNV. Agreement was also...

http://www.evrs.eu/medias/2006/congress/Combination-Therapy-for-Wet-Age-related-Macular-Degeneration-Using-Verteporfin-Photodynamic-Therapy-and-Intravitreal-Bevacizumab.swf Jose Dalma-Weiszhausz, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Ana Suarez- Lincona, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Orlando Ustariz...

Virgilio Morales-Canton, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Lidia Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Myriam L Hernandez-Rojas, (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico) PURPOSE: Evaluate efficacy and safety of intravitreal bevacizumab therapy for neovascular age-related macular degeneration...

Jose Luis Rosales Meneses, MD, PhD (San Cristobal, Venezuela), Pedro P. Bonomo de Oliveira, MD (Sao Paulo, Brazil), Liz J. Florez Ovalles, MD (San Cristobal, Venezuela) PURPOSE: To evaluate the short term safety of systemic bevacizumab (Avastin) and its effects on visual acuity and subfoveal choroidal neovascularization in patients with neovascular age related macular degeneration. METHODS: Open label, single center, uncontrolled clinical...

Derek L. Barker, MD (Tallahassee, FL), H. Logan Brooks, MD (Tallahassee, FL), Robert L. Steinmetz, MD (Tallahassee, FL), Charles K. Newell, MD (Tallahassee, FL), Carmen A. Puliafito, MD (Miami, FL), Philip J. Rosenfeld, MD, PhD (Miami, FL) PURPOSE: Is bevacizumab more effective at preventing vision loss from juxtafoveal macular degeneration than photodynamic therapy? METHODS: A six month retrospective analysis of patients with juxtafoveal...

Alex Melamud, MD (Durham, NC), Sharon Fekrat, MD (Durham, NC),* Jeff Taylor, MD (Raleigh, NC), Sandra S. Stinnett, PhD (Durham, NC) PURPOSE: Do 3 consecutive monthly injections of intravitreal bevacizumab (Avastin®) produce a sustained clinical improvement in eyes with neovascular agerelated macular degeneration? METHODS: We performed a retrospective review of consecutive eyes with all choroidal neovascular lesion subtypes due to...

Paul E. Tornambe, MD (Poway, CA)* PURPOSE: There are concerns that pan VEGF suppression may negatively effect the retinal and choroidal vasculature. The purpose of this paper is to describe what effect pulsed pan-VEGF inhibition using intravitreal Avastin has upon the retinal and choroidal vasculature and the six month response of the sub foveal choroidal neovascular membrane to intravitreal Avastin injections? METHODS: Thirty consecutive...

http://www.evrs.eu/medias/2006/congress/Time to Recurrence of AMD-related CNV Leakage after a Single Initial-Intravitreous-Injection-Bevacizumab-(Avastin):-Implications-for-a-Retreatment.swf Edgar L. Thomas, MD (Beverly Hills, CA)* PURPOSE: To evaluate the time to recurrent leakage on optical coherence tomography after a single initial intravitreous injection of bevacizumab (Avastin) for CNV in AMD METHODS: This is a retrospective chart...

Charles E. Lyon, MD (Shreveport, LA), David H Ren, MD, PhD (Shreveport, LA) PURPOSE: To investigate the visual outcome of intravitreal bevacizumab in treating subfoveal choroidal neovascularization due to age-retlated macular degeneration. METHODS: An open label, nonrandomized, prospective observational study was done on patients with subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. After...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Treatment-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Richard F. Spaide, MD (New York, NY),* Ketan Laud, MD (New York, NY), Howard Fine, MD (New York, NY), James M. Klancnik, MD (New York, NY), Catherine Meyerle, MD (New York, NY), Lawrence Yannuzzi, MD (New York, NY), John Alan Sorenson, MD (New York, NY), Jason S. Slakter, MD...

Andreas Lipski, MD (Essen, Germany), Norbert Bornfeld (Essen, Germany), Mete Gök, Dr. (Essen, Germany), Bernhard Jurklies, Priv.-Doz. Dr. (Essen, Germany) PURPOSE: Electrophysiological and clinical follow-up of central retinal function in patients with minimally classic or occult SRNV in wet ARMD undergoing intravitreal therapy with Pegaptanib-Natrium (Macugen). METHODS: Eight patients with minimally classic and five patients with occult...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-for-Primary-Treatment-of-Neovascular-AMD.swf David F. Williams, MD, MBA (Minneapolis, MN), Steven R. Bennett, MD (Minneapolis, MN), Herbert L. Cantrill, MD (Minneapolis, MN), Jill B. Johnson, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Robert C. Ramsay, MD (Minneapolis, MN), Edwin H. Ryan, MD (Minneapolis, MN), Sundeep Dev, MD (Minneapolis,...

Jaco Lavinsky, MD (Porto Alegre, Brazil), Daniel Lavinsky, MD (Sao Paulo, Brazil), Fabio Lavinsky, MD (Ramat Gan, Israel) PURPOSE: Currently, there are several new therapeutic strategies for exudative AMD being studied, and the main target has been to occlude neovascularization and to obtain an antiangiogenic and antipermeability effect. Our purpose was to study the influence of vascular leakage on the angiographic outcome of Photodynamic...

Alessandro A. Castellarin, MD (Santa Barbara, CA), Robert L. Avery, MD (Santa Barbara, CA),* Dante J. Pieramici, MD (Santa Barbara, CA),* Ma-an A. Nasir, MD (Santa Barbara, CA), Melvin D. Rabena, BS (Santa Barbara, CA), Matthew J. Giust, CRA (Santa Barbara, CA) PURPOSE: To report the safety and biologic effect of intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration in patients followed for a minimum of 6...

Noha Khater, (Cairo, Egypt), Hoda, MH Mostafa, MD (Cairo, Egypt), Mahmoud Soliman (Cairo, Egypt), Tamer Macky, MD (Cairo, Egypt) PURPOSE: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) in the treatment of subfoveal choroidal neovascularization (CNV) caused by age related macular degeneration (AMD) and myopia. METHODS: Fifteen eyes from 15 patients with subfoveal CNV caused by AMD (n=10)...

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: The VeriTAS study is designed to evaluate the efficacy and safety of verteporfin PDT combined with either intravitreal triamcinolone acetonide or pegaptanib sodium to treat subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The 24-month randomized, double-masked VeriTAS study enrolled patients at 50 centers in the U.S. METHODS: Inclusion criteria:...

ThucAnh Thi Ho, MD (Chicago, IL), Pauline Townsend Merrill, MD (Chicago, IL) PURPOSE: To evaluate the role of combined intravitreal pegaptanib and photodynamic therapy with verteporfin (PDT) in the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We performed a retrospective review on 11 eyes of 11 patients treated with combined pegaptanib and PDT. Pre-treatment and...

David Hauser, MD (Kefar Bilu B, Israel), Yoel Greenvald, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Haya Katz, MD (Rehovot, Israel), Reut Parnes, MD (Rehovot, Israel), Nir Shoham, (Rehovot, Israel), Genady Landa, MD (Rehovot, Israel), Ayala Pollack, MD (Rehovot, Israel) PURPOSE: To compare the outcome of intravitreal triamcinolone (Kenalog) and intravitreal bevacizumab (Avastin) for eyes with serous PED and occult choroidal...

http://www.evrs.eu/medias/2006/congress/Prolonged-Choroidal-Hypofluorescence-Following-Verteporfin-PDT-Combined-with-Intravitreal-Triamcinolone-Acetate-Injection-for-Agerelated-CNVM.swf Jeffrey K. Luttrull, MD (Ventura, CA), Charles A Spink, CRA (Ventura, CA) PURPOSE: To determine the incidence and effect of prolonged choroidal hypofluorescence (PCH) following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetate...

Salvatore Grisanti, MD (Tuebingen, Germany), Olcay Tatar, MD (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Annemarie Adam, (Tuebingen, Germany), Klaus Lucke, MB ChB (Bremen, Germany), Claus Eckardt, MD (Frankfurt, Germany), Peter Stalmans, MD, PhD (Leuven, Belgium), Tillmann Eckert, MD (Frankfurt, Germany), Silvia Bopp, MD (Bremen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany) PURPOSE: To evaluate the impact of...

Calvin A. Grant, MD (Oak Lawn, IL) PURPOSE: To offer submacular surgery with combined RPE/choroid graft for patients that are ineligible for PDT and anti-VEGF agents for possible visual rehab. METHODS: 12 consecutive patients underwent submacular surgery with combined RPE/choroid graft as a prospective case control series. The patients had profound visual loss as a result of fibrosis in the subretinal space and choroid or atrophy of the...

http://www.evrs.eu/medias/2006/congress/Six-month-Follow-up-on-50-Consecutive-Patients-with-Intravitreal-Bevacizumab-Injections-for-Neovascular-Age-Related-Macular-Degeneration.swf Samira Khan, (Albany, NY), Paul M. Beer, MD (Albany, NY), Naomi S. Falk, MD (Albany, NY), Amjad Hammad, MD (Albany, NY), Martin O’Malley, MD (Albany, NY) PURPOSE: 6 months results of intravitreal Bevacizumab on patients with neovascular ARMD. METHODS: A...

http://www.evrs.eu/medias/2006/congress/Recurrent-Choroidal-Neovascularization-after-Macular-Translocation-Surgery-with-360-degree-Peripheral-Retinectomy.swf WINNER 2006 BAUSCH & LOMB RETINA FELLOWS’ FORUMRESEARCH AWARD Claxton Baer, MD (Durham, NC), Catherine Bowes Rickman, PhD (Durham, NC), Sunil Srivastava, MD (Atlanta, GA), Goldis Malek, PhD (Durham, NC), Sandra Stinnett, DrPH (Durham, NC), Cynthia A. Toth, MD (Durham,...

http://www.evrs.eu/medias/2006/congress/Intravitreally-Injected-Anti-VEGF-Drugs-Exert-a-Biological-Effect-in-the-Fellow-Eye.swf Tongalp H. Tezel, MD (Louisville, KY), Charles C. Barr, MD (Louisville, KY), Henry J. Kaplan, MD (Louisville, KY) PURPOSE: To determine whether the intravitreal injection of anti-VEGF drugs (Kenalog, Macugen, Avastin) exert any biological effect in the fellow eyes of patients with bilateral exudative...

Giovanni Staurenghi, MD (Milan, Italy), Chiara Veronese, MD (Mississauga, Canada),* Garzia Levi, MD (Milan, Italy), Paolo Danzi, MD (Brescia, Italy), Robert Flower, MD (Baltimore, MD), Robert G. Devenyi, MD (Toronto, Canada) PURPOSE: To compare near-IR laser-only FVT with ICG dye-enhanced photocoagulation (DEP) using a device that enables visualization of the FV during treatment in a clinical trial. METHODS: 40 subjects randomized to FVT or...

Clement K. Chan, MD (Palm Springs, CA), Carsten H. Meyer, MD (Marburg, Germany), Jeffrey G. Gross, MD (Columbia, SC), Prema Abraham, MD (Rapid City, SD),* Steven G. Lin, MD (Palm Springs, CA), Asha S.D. Nuthi, DO (Palm Springs, CA) PURPOSE: To report a case series of retinal pigment epithelial (RPE) tears after off-label intraocular bevacizumab (Avastin) for neovascular age-related macular degeneration. Acute RPE tears are known to occur...

K.V. Chalam, MD, PhD (Jacksonville, FL), Shailesh Kumar Gupta, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), Swati Agarwal, MD (Jacksonville, FL) PURPOSE: Evaluation of Relationship between VEGF levels and Age Related Macular Degeneration. METHODS: 27 aqueous humors samples were collected at multiple sessions from 19 eyes of 19 patients with choroidal neovascular membranes (CNV), secondary to age related macular...

http://www.evrs.eu/medias/2006/congress/The-Value-and-Cost-effectiveness-of-Interventions-for-Subfoveal,-Neovascular,-Age-related-Macular-Degeneration-(ARMD).swf Melissa M. Brown, MD, MN, MBA (Flourtown, PA),* Gary C. Brown, MD, MBA (Wyndmoor, PA)* PURPOSE: To assess the value of interventions utilized for the treatment of subfoveal, neovascular, agerelated macular degeneration (ARMD) employing evidencebased data from clinical trials...

Francesco Boscia, MD (Bari, Italy), Ugo Introini, MD (Milano, Italy), Alfredo Pece, MD (Melegnano (mi), Italy), Francesco Prascina,  MD (Foggia, Italy), Michele Reibaldi, MD (Catania, Italy), Claudio Furino, (Bari, Italy), Caterina Papadopolou, MD (Bari, Italy), Giancarlo Sborgia, MD (Bari, Italy) PURPOSE: Large randomized clinical trials of laser photocoagulation, photodynamic therapy (PDT) with verteporfin and antiangiogenic drugs have...

Neil M. Bressler, MD (Baltimore, MD), Chantal M. Dolan, PhD (South San Francisco, CA),* Jennifer Fine, ScD (South San Francisco, CA),* Claudine Marceau, MBA, MSc (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of ranibizumab (LucentisTM) on patient-reported vision-specific quality of life (QoL) using the NEI-VFQ 25 through 12 months in subjects with predominantly classic subfoveal choroidal...

Gregory R. Blaha, MD, PhD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)* PURPOSE: To report our experience with combination low-fluence PDT. METHODS: An IRB-approved, retrospective chart review of all patients receiving low-fluence (50% standard) PDT (LFPDT) at our institution was performed. RESULTS: Twenty five eyes of 24 patients received LFPDT. Two eyes did not receive combination therapy, two received Macugen (Pegaptanib,...

http://www.evrs.eu/medias/2006/congress/Ranibizumab-(LucentisTM)-Vision-specific-Quality-of-Life-through-24-Months-in-Neovascular-AMD-Subjects-in-MARINA:-A-Phase-III-Clinical-Trial.swf Tom S. Chang, MD (Pasadena, CA),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Neil M. Bressler, MD (Baltimore, MD)* PURPOSE: To examine the effects of ranibizumab...

Alay S. Banker, MD (Ahmedabad, India), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela), Ajay Dudani, MD (Mumbai, India) PURPOSE: To determine the results of combination triple therapy for choroidal neovascularization (CNV). METHODS: Prospective pilot study of 11 consecutive eyes with new (previously untreated) CNV which were treated with photodynamic therapy (PDT) with visudyne along with intravitreal bevacizumab (1.25mg) and subtenon...

Sebastian Wolf, MD (Bern, Switzerland),* Thomas C. Hohman, PhD (East Hanover, NJ),* PROTECT Study Group PURPOSE: To evaluate the safety and explore the efficacy of same-day administration of verteporfin and intravitreal injection of liquid ranibizumab 0.5mg. METHODS: PROTECT is an open label, multicenter, Phase II, 9 month study, in patients with predominantly classic (n=13) or occult (n=19), subfoveal CNV secondary to AMD. Verteporfin was...

http://www.evrs.eu/medias/2006/congress/Sub-Retinal-Injection-of-Bevacizumab-(Avastin)-in-Treating-Neovascular-Age-Related-Macular-Degeneration,-25-Gauge-Approach.swf http://www.evrs.eu/medias/2006/congress/Sub-Retinal-Injection-of-Bevacizumab-(Avastin)-in-Treating-Neovascular-Age-Related-Macular-Degeneration,-25-Gauge-Approach.flv Ehab N. El-Rayes, MD (Cairo, Egypt) PURPOSE: Experimental studies have demonstrated that vascular endothelial...

Rajendra S. Apte, MD, PhD (St. Louis, MO), Thomas A. Ferguson, PhD (St. Louis, MO), Jennifer Richter, BS (St. Louis, MO), John Herndon, BS (St. Louis, MO) PURPOSE: CNV is the process by which abnormal blood vessels develop underneath the retina and lead to blindness in over 90% of patients with AMD. Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response has been thought to be...

http://www.evrs.eu/medias/2006/congress/An-OCT-guided-Variable-dosing-Regimen-with-LucentisTM-(Ranibizumab)-in-Neovascular-AMD:-One-Year-Results-from-the-PrONTO-Study.swf Philip J. Rosenfeld, MD, PhD (Miami, FL),* Carmen A. Puliafito, MD, MBA (Miami, FL),* Anne E. Fung, MD (San Francisco, CA),* Geeta A. Lalwani, MD (Miami, FL), Stephan Michels, MD (Vienna, Austria),* William J. Feuer, MS (Miami, FL) PURPOSE: To determine if an OCT-guided...

Swati Agarwal, MD (Jacksonville, FL), Shailesh Gupta, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), K.V. Chalam, MD, PhD (Jacksonville, FL), Sweta Tarigopula, BS (Jacksonville, FL) PURPOSE: To correlate the optical coherence tomography and Heidelberg retinal angiography findings in patients treated with intravitreal bevacizumab for choroidal neovascular membranes. METHODS: 12 patients with choroidal neovascular membranes...

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-FA-OCT-Results-in-a-Study-of-Ranibizumab-(LucentisTM)-for-Choroidal-Neovascularization-(CNV)-Due-to- Agerelated-Macular-Degeneration-(AMD).swf William F. Mieler, MD (Chicago, IL) PURPOSE: PIER is a 2-year study of the safety/efficacy of 0.3-and 0.5mg doses intravitreal ranibizumab, injected monthly for 3 doses and then every 3 months, vs. Sham injections in AMD patients with CNV lesions...

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-Results-of-a-Phase-IIIB-Study-of-Ranibizumab- Efficacy-and-Safety-in-Choroidal-Neovascularization-Due-to-Age-related-Macular-Degeneration.swf Prema Abraham, MD (Rapid City, SD),* Huibin Yue, PhD (South San Francisco, CA),* Naveed Shams, MD, PhD (South San Francisco, CA)* PURPOSE: PIER is a 2-year study of the safety and efficacy of intravitreal injections of 2 different doses (0.3 and 0.5...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Ranibizumab-(LucentisTM)-Plus-Verteporfin- Photodynamic-Therapy-for-Neovascular-Age-related-Macular- Degeneration:-FOCUS-2-year-Results.swf Andrew N. Antoszyk, MD (Charlotte, NC),* Debbi Kotlovker, (San Francisco, CA),* Sharon O’Byrne, (San Francisco, CA)* PURPOSE: The 2-year FOCUS study compared the safety and efficacy of monthly intravitreal injections of ranibizumab (Lucentis) in...

http://www.evrs.eu/medias/2006/congress/Consistency-of-Effect-of-Ranibizumab-at-2-Doses-on-Contrast- Sensitivity-in-3-Phase-III-and-IIIB-Studies-of-Patients-with-CNV- Secondary-to-AMD.swf Jean-Francois Korobelnik, MD (Bordeaux, France)* PURPOSE: To examine the consistency of effect of intravitreal ranibizumab on contrast sensitivity in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly...

http://www.evrs.eu/medias/2006/congress/Two-year-Efficacy-and-Safety-Results-from-the-MARINA-Study.swf Ursula Schmidt-Erfurth, MD (Vienna, Austria), George A.Williams, MD (Royal Oak, MI), for the MARINA Study Group PURPOSE: The MARINA study is a 2-year, Phase III, multicenter, randomized, double-masked, sham injectioncontrolled study designed to evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab used as a...

Paolo Lanzetta, MD (Udine, Italy),* MARINA and ANCHOR Study Groups PURPOSE: To examine the consistency of safety across two studies of ranibizumab in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly classic, minimally classic and occult lesions with no classic component. METHODS: Ranibizumab has been tested in 2 Phase III, randomized, multicenter, double-masked, controlled studies of...

Cynthia A. Toth, MD (Durham, NC), Marcin Stopa, MD (Poznan, Poland), Joseph Izatt, PhD (Durham, NC),* Bradley A. Bower, PhD (Durham, NC), Brian Dodge, (Durham, NC) PURPOSE: Pathology data from three-dimensional imaging of the fundus with spectral domain optical coherence tomography (SDOCT) can be extracted, cross-correlated with conventional retinal imaging and retinal function data, and can be precisely monitored over time. Such data would...

Alain Zourdani, MD (Creteil, France), Patricia Haymann, MD (Creteil, France), Joelle Marciano, MD (Creteil, France), Eric Souied, MD (Creteil, France), Gabriel J. Coscas, MD (Creteil, France), Gisele Soubrane, MD (Creteil, France) PURPOSE: A pre requisite for a successful treatment of age related macular degeneration (AMD) requires preservation of functional macular photoreceptors. The aim of this study was to establish potential...

http://www.evrs.eu/medias/2006/congress/Combined-Efficacy-of-Intravitreal-Ranibizumab-in-Two-Phase-III-Studies-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Anat Loewenstein, MD (Tel Aviv, Israel),* MARINA and ANCHOR Study Group PURPOSE: Is Ranibizumab effective in the treatmentof CNV secondary to AMD? METHODS: Ranibizumab has been tested in two Phase III,randomized, multicenter, double-masked, controlled...

http://www.evrs.eu/medias/2006/congress/Active-Choroidal-Neovascularization-without-Subretinal-or-Intraretinal-Fluid-on-OCT-Imaging.swf G. Baker Hubbard, MD (Atlanta, GA) METHODS: Retrospective chart review. RESULTS: Two cases of active CNV due to age-related macular degeneration (AMD) and one case of CNV secondary to juxtafoveal telangiectasis (JFT) were identified. The AMD cases had been previously treated for CNV. The JFT case was not...

http://www.evrs.eu/medias/2006/congress/Combined-Photodynamic-Therapy-with-Verteporfin-and-Intravitreal-Bevacizumab-for-Subfoveal-Choroidal-Neovascularization-in-AMD.swf David M. Misch, MD (Winter Haven, FL), Michael J. Tolentino, MD (Winter Haven, FL),* Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, FL) PURPOSE: To determine the safety and efficacy of combined intravitreal Bevacizumab (Avastin) with photodynamic...

Zoran Tomic Purpose: To report on our results with full macular translocation (FMT) in the treatment of ARMD. Methods: Retrospective study on 15 consecutive eyes that underwent FMT for the treatment of subfoveal CNV in ARMD. Results: Visual acuity improved by ≥ 2 lines Snellen in 6 operated eyes (40%), remained unchanged in 3 eyes (20%) and worsened in 6 (40%). Reading vision recovered in 5 eyes (33%) and maintained in 2 (13%)....

Frank Koch, MD, 1, Lars-Olof Hattenbach, MD, 1, Albert Augustin, MD, 2 – 1 University Eye Clinic Frankfurt/M., Germany, 2. Staedt. Kliniken Karlsruhe, Germany Purpose: To summarize the treatment potentials of steroid injections w/o laser coagulation for treatment of the macula in ARMD. Methods: Triamcinolone (0.4 to 20 mg) is injected intravitreally and/or subretinally. Subthreshold laser is applied transretinally or subretinally through...

Ziya Kapran, Tugrul Altan, Mehmet Çakır, Nur Acar, Yaprak B. Ünver, Aslı Utine, Zerrin Bayraktar Purpose: Evaluation of the results of surgical extraction of the choroidal neovascular membranes (CNVM). Methods: Four eyes of 4 patients who underwent surgical extraction of CNVM between July 2002 and July 2003 were retrospectively evaluated. Complications, visual prognosis, and recurrence rate were recorded. Results: The etiology of the...

http://www.evrs.eu/medias/2005/congress/Rheopheresis-to-Eradicate-the-Drusen-CNV-Cascade.swf Frank Koch, MD, 1, Reiner Klingel, MD, 2, Cordula Fassbender, MD, 2 – 1 University Eye Clinic, Frankfurt/Main, Germany, 2 Apheresis Research Institute, Cologne, Germany Purpose: To update the current results of rheopheresis. Methods: Elimination of excact defined spectrum of high-molecular proteins from the blood circulation. The rheopheresis is...

http://www.evrs.eu/medias/2005/congress/Histological-charateristics-of-neovascular-membranes-in-AMD-after-PDT:-Comparison-with-spontaneous-evolution,-laser-photocoagulation-and-radiotherapy.swf Didier Ducournau, Nantes, France, Yvette Ducournau – Nantes, France Purpose: To describe and emphasize specific histological changes observed on removed neovascular membranes after PDT in order to understand the post treatment complication and the...

http://www.evrs.eu/medias/2005/congress/Photodynamic-Therapy-for-Choroidal-Neovascularization-in-Juvenile-Disciform-Macular-Degeneration.-Case-Report-of-Four-Icelandic-Cases.swf Ingimundur Gislason, MD, Fridbert Jonasson, MD, Thordur Sverrisson, MD – Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland Purpose: To evaluate the result of PDT treatment for choroidal neovascularization in juvenile disciform...

http://www.evrs.eu/medias/2005/congress/Encouraging-results-of-photodynamic-therapy-with-verteporfin-in-a-clinical-patient-material-of-age-related-macular-degeneration-and-choroidal-neovascularization.swf Christina Frennesson, MD, PhD, Sven Erik Nilsson, MD, PhD Purpose: To investigate the effects of photodynamic therapy (PDT) on sub- and juxtafoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a clinical...

http://www.evrs.eu/medias/2005/congress/Hypothesis:-Is-vitreous-adhesion-a-risk-factor-for-CNV-in-AMD.swf Martine Mauget-Faÿsse, Maddalena Quaranta El Maftouhi, Margara Zanotele, François Devin Purpose: The relationships between posterior vitreous and retina have been poorly described in vivo in exudative AMD. In a previous study (ARVO 2003), high prevalence of abnormalities of the vitreo-retinal interface have been found in exudative AMD...

Lennart Berglin, MD, PhD – St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden Many signs indicate an inflammatory reaction and a molecular breakdown of the bloodretina barrier in Bruchs membrane with age in choroidal neovascularization (CNV). The vascular response has many similarities with an unspecific wound healing process elsewhere in the body. New vessel growth (angiogenesis) can be triggered by a switch in a normally...

F. Gelisken, K. U. Bartz-Schmidt for the Tuebingen Study Group Purpose: To report the change of the mean visual acuity of the patients enrolled in the Full Macular Translocation (FMT) vs. Verteporfin Photodynamic Therapy (PDT) study for subfoveal, predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Monocenter, prospective, controlled, randomized, clinical, pilot study....